Form 4: BridgeBio Pharma Director Receives Equity Compensation, Reports Unexplained Share Disposition

BridgeBio Pharma, Inc. director Hannah Valantine was granted restricted stock units and stock options, while also reporting a disposition of common stock at zero cost.

Summary

• Director Hannah Valantine of BridgeBio Pharma, Inc. (BBIO) was granted 6,589 Restricted Stock Units (RSUs) on June 20, 2025, with a price of $0 per unit.
• These RSUs will vest in three equal annual installments, with one-third vesting each year after June 20, 2025, and full vesting by June 20, 2028, contingent on her continued service on the board.
• Additionally, Ms. Valantine was granted 8,425 stock options on June 20, 2025, with an exercise price of $41.73 per share and an expiration date of June 19, 2035.
• Similar to the RSUs, one-third of the shares underlying these stock options will vest annually after June 20, 2025, achieving full vesting by June 20, 2028, subject to continued board service.
• The filing also reported a disposition of 8,353 shares of common stock at a price of $0 on June 20, 2025, the nature of which is not explicitly detailed in the explanations.
• Following the reported transactions, Ms. Valantine directly beneficially owns 8,353 shares of common stock and 8,425 stock options, and indirectly owns 3,433 shares through her spouse.

Sentiment

Score: 6

Explanation: The sentiment is generally positive due to routine equity compensation aligning director interests with shareholders, but slightly tempered by the unexplained disposition of shares at zero cost.

Positives

• The grant of 6,589 Restricted Stock Units (RSUs) and 8,425 stock options aligns the director's financial interests with those of the shareholders, promoting long-term value creation.
• The vesting schedule for both RSUs and stock options, tied to continued service until June 20, 2028, encourages long-term commitment from the director.

Negatives

• The disposition of 8,353 shares of common stock at a $0 price on the same day as the equity grants is unclear and unexplained, potentially indicating a forfeiture, reclassification, or a large tax withholding event without further context.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continued service on the Issuer's board of directors, meaning the compensation is contingent on future engagement.
• The unexplained disposition of 8,353 shares at $0 could be a risk if it represents a forfeiture or an adverse event not fully disclosed.

Future Outlook

The future outlook indicates that the director's equity compensation (RSUs and stock options) will vest over the next three years, contingent on her continued service on the board of directors until June 20, 2028.

Industry Context

The grant of equity compensation, such as Restricted Stock Units and stock options, to directors is a standard practice in the biotechnology and pharmaceutical industry. This approach is widely used to attract and retain talent, align the interests of board members with long-term shareholder value, and incentivize performance within a highly competitive sector.

Corporate Governance

Related Party Transactions

• The equity grants to Director Hannah Valantine constitute related party transactions, which are standard for director compensation.
• 3,433 shares of common stock are indirectly beneficially owned by Hannah Valantine through her spouse.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon RSU vesting and option exercise, but also improved alignment of director interests with shareholder value through equity compensation.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Continued service of Hannah Valantine on the BridgeBio Pharma, Inc. board of directors.
• Annual vesting of RSUs and stock options on June 20, 2026, June 20, 2027, and June 20, 2028.
• Potential exercise of stock options by June 19, 2035.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership